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During viral infection, inflammation and recovery are tightly controlled by competing proinflammatory and regulatory immune
pathways. Respiratory syncytial virus (RSV) is the leading global cause of infantile bronchiolitis, which is associated with recur-
rent wheeze and asthma diagnosis in later life. Th2-driven disease has been well described under some conditions for RSV-in-
fected mice. In the present studies, we used the Foxp3DTR mice (which allow specific conditional depletion of Foxp3 T cells) to
investigate the functional effects of regulatory T cells (Tregs) during A2-strain RSV infection. Infected Treg-depleted mice lost
significantly more weight than wild-type mice, indicating enhanced disease. This enhancement was characterized by increased
cellularity in the bronchoalveolar lavage (BAL) fluid and notable lung eosinophilia not seen in control mice. This was accompa-
nied by abundant CD4 and CD8 T cells exhibiting an activated phenotype and induction of interleukin 13 (IL-13)- and
GATA3-expressing Th2-type CD4 T cells that remained present in the airways even 14 days after infection. Therefore, Treg cells
perform vital anti-inflammatory functions during RSV infection, suppressing pathogenic T cell responses and inhibiting lung
eosinophilia. These findings provide additional evidence that dysregulation of normal immune responses to viral infection may
contribute to severe RSV disease.
Viral lung infections lead to impairment of lung function bymultiple mechanisms, including the obstruction of airflow by
inflammatory cells in the conducting airways, immune infiltration
of lung tissue, and alveolar edema (1, 2). The safe elimination of
infection requires a precise control of inflammation, sufficient to
control the pathogen load but limiting the severity of immunopa-
thology. An improved understanding of the checks and balances
governing the immune response to infectionmay assist not only in
understanding the immune system but also in developing new
treatments and in creating effective vaccines (3).
Human respiratory syncytial virus (RSV) infection is the lead-
ing cause of severe lower respiratory tract disease, causing infantile
bronchiolitis and significant morbidity and mortality in the el-
derly (1, 4–6). It is estimated that RSV infects 33.8million children
under 5 years old each year, killing between 66,000 and 199,000
children globally. Virtually all these deaths occur in developing
countries (7, 8); almost all children have been infected at least
once by the age of 3 (8). An overexuberant immune response to
infection is thought to underlie the pathogenesis of bronchiolitis.
Prevention of RSV infection during infancy reduces the likelihood
of recurrent wheezing in later life (9), showing that RSV infection
can lead to the development of asthma in some children.
Regulatory T (Treg) cells are a subset of CD4 T cells that
specifically express the forkhead box P3 (Foxp3) transcription fac-
tor and play an essential role in dampening immune responses
and preventing autoimmune disease (10–12). The importance of
Treg cells to immune homeostasis is illustrated by humans suffer-
ing from immunodysregulation, polyendocrinopathy, enteropa-
thy, X-linked (IPEX) syndrome due to mutations in the Foxp3
gene (13). This pathology is mimicked in Foxp3-deficient Scurfy
mice, which likewise suffer from a progressive and fatal spontane-
ous multiorgan inflammatory disease (14, 15).
Treg cells can regulate the response to several viral infections
(16–23). During RSV infection, Treg cells limit antigen-specific T
cell responses, suppress inflammation, and may help to control
viral replication (24–26). However, there is still uncertainty about
how Treg cells control the immune response during RSV, in part
due to the use of different strategies to deplete Treg cells in vivo.
Several initial reports used the anti-CD25 PC61 antibody, which
binds and depletes cells expressing the high-affinity interleukin 2
(IL-2) receptor alpha chain CD25 (24–26). While CD25 is highly
expressed on Foxp3 Treg cells, this receptor is also expressed on
activated T cells, and therefore use of PC61 may additionally de-
plete non-Treg cells (27). More specific depletion strategies have
been developed using bacterial artificial chromosome (BAC)
transgenic and knock-in mice in which the Foxp3 gene locus is
modified by insertion of a human diphtheria toxin receptor
(DTR)-enhanced green fluorescent protein (eGFP) element (28,
29). Upon treatment with diphtheria toxin, the DTR-expressing
Foxp3 Treg cells may be specifically killed while all other host
cells are unaffected (30). Using BAC-transgenic DEREG (deple-
tion of regulatory T cell) mice, we have previously shown that
Tregs require granzyme B expression to cause functional regula-
tion during RSV disease (31). We also have shown that boosting
Treg cells using the IL-2/IL-2 receptor (IL-2R) complex amelio-
rates aspects of disease during primaryRSV infection (31) and that
RSV disease augmented by prior vaccination with formalin-inac-
tivated vaccine (FI-RSV) is accompanied by the virtual disappear-
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ance of Tregs from the airways (32). Importantly, recruitment of
Treg cells into the airways by administration of CCL17 andCCL22
intranasally ameliorates vaccine-enhanced FI-RSV disease (32).
Taken together, these studies suggest that Tregs modulate the im-
mune response to RSV infection and that severe RSV disease may
be caused by dysregulated immune responses to infection.
Previous studies used methods that partially or transiently de-
plete Tregs. In the case of the DEREG mice, diphtheria toxin ad-
ministration causes 95 to 98%depletion of Treg cells by apoptosis,
but this is transient due to the leaky nature of the BAC transgene;
over time, Foxp3Treg cells that do not express the transgene and
thus cannot be depleted appear (30). Therefore, to examine the
effects of more-complete Treg cell depletion during RSV infec-
tion, we used the Foxp3DTR mouse model. The Foxp3DTR mice are
a knock-in strain created using a targeting vector consisting of a
human DTR fused to GFP and containing an internal ribosome
entry sequence (IRES) that inserts into the 3= untranslated region
of the Foxp3 gene locus. Similar to the case with DEREG mice,
both the DTR and GFP are exclusively expressed in Foxp3 Treg
cells in Foxp3DTR mice, and diphtheria toxin treatment in these
mice specifically induces apoptosis of Foxp3 Treg cells (33).
Interestingly, although normal C57BL/6 mice are relatively re-
sistant to RSV infection, depletion of Tregs from the C57BL/6-
background Foxp3DTR mice caused marked weight loss and en-
hanced cellular influx into the lungs and airways without affecting
viral clearance. Inflammatory T cell responses to RSV infection
were enhanced, with increased expression ofGzmB andCD11a on
CD4 and CD8 T cells. Most notably, there was a marked and
persistent eosinophilic response in the airways of the Treg-de-
pleted mice, indicative of Th2-mediated pathology. This was as-
sociated with increased IL-13 and gamma interferon-positive
(IFN-) CD4 T cell recruitment to the lungs and enhanced
expression of the Th2-defining transcription factor Gata3 in the
airways. Thus, we highlight novel functions for Treg cells in shap-
ing the CD4 effector cell response during RSV infection and
promoting resolution of pathology.
MATERIALS AND METHODS
Mice, virus stocks, and infection. Six- to ten-week-old C57BL/6 wild-
type (purchased fromHarlan, United Kingdom) and Foxp3DTRmice were
housed under specific-pathogen-free conditions according to UK Home
Office guidelines.
Plaque-purified human RSV (A2 strain from ATCC) was grown to a
high titer in HEp-2 cells. Age-matched wild-type (WT) and Foxp3DTR
mice were lightly anesthetized with isofluorane and challenged intrana-
sally (i.n.) with a dose of 8  105 focus-forming units (FFU) of RSV on
day 0.
Diphtheria toxin treatment. Foxp3DTR mice were injected with 0.75
g of diphtheria toxin (DT) (unnicked,Corynebacterium diphtheria from
Merck Millipore, United Kingdom) in phosphate-buffered saline (PBS)
intraperitoneally (i.p.) on days1 and 3 during RSV infection to acutely
deplete Foxp3 Treg cells.
Cell isolation andprocessing.Micewere culled using a fatal dose (100
to 150 l) of pentobarbital injected i.p. according the UK Home Office
guidelines. Bronchoalveolar lavage (BAL) cells were collected by inserting
a syringe with a cannulated needle into the trachea and flushing 3 times
with 1 ml of PBS supplemented with 12 mM lidocaine powder (Sigma).
Lung lobes were collected and digested with collagenase XI (25 g/ml;
Sigma) using a gentleMACs cell dissociator (Miltenyi Biotech) according
to the manufacturer’s protocol. Spleen and lung cells were mashed
through 100 M cell strainers to create single-cell suspensions. Total cell
counts were determined by flow cytometry using Count Bright counting
beads (Invitrogen), and dead cells were excluded by staining for 7-amino-
actinomycin D (7-AAD) (Sigma). To determine the cellular composition
in the BAL fluid, cells were transferred onto a microscope slide (Thermo
Scientific, United Kingdom) using a Shandon Cytospin 3 centrifuge, and
slides were stained with hematoxylin and eosin (H&E) (Reagena, Gami-
dor, United Kingdom). Cells were categorized as macrophages or mono-
cytes, lymphocytes, neutrophils, and eosinophils based on theirmorphol-
ogy and size using the Axio Scope.A1 light microscope (Zeiss).
Photographs of slides were taken using the AxioCam Erc 5s (Zeiss) at
magnification40.
Real-time quantitative PCR for viral load. Total RNA was extracted
from homogenized lung tissue using the Stat60-RNA extraction reagent
(AMS Biotechnology Ltd., United Kingdom) and transcribed to cDNA
using random hexamers and the Omniscript reverse transcriptase kit
(Qiagen, United Kingdom). Real-time quantitative PCR was performed
for the RSV large (L) polymerase gene using primers and probes described
previously (26) and Quantitect probe PCR master mix (Qiagen). RSV
L-gene copy numbers were normalized to the 18S rRNA housekeeping
gene.
Chemokine and cytokine detection. Eotaxin and IL-5 in the BAL
fluid were measured using a custom-made 10-plex Milliplex MAPmouse
cytokine/chemokine kit and assayed according to the manufacturer’s in-
structions (MerckMillipore), and data were acquired on the Bio-Plex 200
system (Bio-Rad Laboratories, Hemel Hempstead, United Kingdom).
The concentrations of cytokines and chemokines were determined from a
standard curve using the Bio-Plex 6 software (Bio-Rad Laboratories). De-
tection limits were 3.2 pg/ml (lower) and 2,000 pg/ml (upper) for IL-5 and
3.2 pg/ml (lower) and 10,000 pg/ml (upper) for Eotaxin.
Flow cytometry. For flow cytometry analysis, dead cells were discrim-
inated using Live/Dead fixable red dead cell stain (Invitrogen) according
to the manufacturer’s instructions. Cells were incubated in fluorescence-
activated cell sorter (FACS) buffer (1 PBS containing 1% bovine serum
albumin [BSA] and 5mMEDTA)with antibody recognizing the Fc II/III
receptor (BD Biosciences) and then with the following antibodies (pur-
chased from BD) unless otherwise stated: phycoerythrin (PE)-Cy7-con-
jugated anti-CD3 (clone 145-2C11), V450-conjugated NKp46(CD335)
(clone 29A1.4), allophycocyanin (APC) H7- or APC Cy7-conjugated an-
ti-CD4 (clone GK1.5), Alexa Fluor 700-conjugated anti-CD8a (clone 53-
6.7), and PE conjugated anti-CD11a (clone 2D7). Intracellular staining of
Foxp3, T-bet, Gata3, and GzmB was performed using the Foxp3 staining
kit (eBioscience) according to the kit protocol and the following antibod-
ies: Alexa Fluor 488-conjugated anti-Foxp3 (clone FJK-16S), PE-conju-
gated anti-human/mouse T-bet (clone 4B10), and eFluor 660-conjugated
anti-human/mouse Gata3 (clone TWAJ) (all purchased from eBiosci-
ence) and APC-conjugated anti-human GzmB (GB12; Invitrogen).
Briefly, cells were fixed for 30min in fixation buffer, washed with FACS
buffer, and then incubated in permeabilization buffer with antibodies
for 1 h.
For intracellular detection of IFN- and IL-13, fresh cells were stimu-
lated in 96-well plates with 100 ng/ml of phorbol myristate acetate (PMA)
and 1g/ml of ionomycin or with 5g/ml ofM peptide (187-195; NAIT-
NAKII; Anaspec) in complete Dulbecco modified Eagle medium
(DMEM) supplementedwith 10% fetal bovine serum, 2mML-glutamine,
100U/ml penicillin, and 100g/ml streptomycin. After 1 h of incubation,
monensin (Golgi Stop; BD) was added. Cells were incubated for a further
3 h, washed, and stained for surface receptors. Intracellular cytokine stain-
ing was performed using the Cytofix/Cytoperm kit (BD) according to the
manufacturer’s instructions using peridinin chlorophyll protein (PerCP)
Cy5.5-conjugated anti-IFN- antibody (clone XMG1.2; eBioscience) and
PE-conjugated anti-IL-13 antibody (clone eBio13a; eBioscience). Stimu-
lation with the M peptide was for 6 h, and monensin was added after 1 h.
Cells were acquired on the LSR II or the Fortessa (BD) instrument, and
data were analyzed using FlowJo software (version 7.6.5). Cells were gated
for live cells, singlets, and lymphocytes and then analyzed for the relevant
markers.
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Statistical analysis. Results are presented as means standard errors
of the means (SEM). Statistical significance was determined using a non-
parametricMann-Whitney test (, P 0.05; , P 0.01; , P 0.001;
, P 0.0001). P values of0.05 were considered significant (Prism
software; Graph-Pad Software Inc.).
RESULTS
Regulatory T cells limit and control inflammation after RSV in-
fection. C57BL/6 mice can be infected with RSV but are more
resistant to RSV-induced illness than the BALB/c mice used in
most RSV studies (31). We infected wild-type (WT) C57BL/6 or
Foxp3DTR (DTR/DT)C57BL/6mice intranasally with 8 105 FFU
of human A2 RSV on day 0. Foxp3DTR (DTR/DT) mice were de-
pleted of Foxp3 Treg cells by injection of diphtheria toxin (DT)
intraperitoneally (i.p.) on days 1 and 3. Depletion was highly
effective, removing 90% of Treg cells from the lungs of
Foxp3DTR mice (DTR/DT/RSV) on day 4 postinfection compared
to results for wild-type (WT/RSV) controls (see Fig. S1A in the
supplemental material). The frequency of Tregs remained signif-
icantly reduced to day 8 in both the airways (BAL) and lungs of
depletedDTR/DTmice (see Fig. S1B), although the total numbers
of Foxp3 Treg cells rebounded by day 8 postinfection in the
airways (see Fig. S1C). A significant loss of Treg cells was also seen
in uninfected Treg-depleted mice (DTR/DT) compared to results
for naive WT controls (see Fig. S1A and B).
Using weight loss as a measure of disease, we found that the
depletion of Tregs (DTR/DT/RSV) made mice more susceptible
to disease, enhancing weight loss beginning at day 7 and persisting
until day 14 postinfection compared to results for wild-type con-
trols (WT/RSV) (Fig. 1A). Pulmonary inflammation (assessed by
determining total cellular influx in the lungs and airways [BAL
fluid]) was significantly enhanced on day 8 postinfection in Treg-
depleted DTR/DT/RSV mice compared to that of WT/RSV con-
trols (Fig. 1B). Furthermore, the inflammation persisted until at
least day 14 postinfection in Treg-depleted mice.
One explanation for the enhanced pathology observed in the
absence of Treg cells could be an inability to clear the virus. How-
ever, when the RSV L gene was measured in the lungs of mice on
day 4 (peak virus load) and day 8 (virus clearance) postinfection,
there was no detectable difference betweenWT andTreg-depleted
mice (Fig. 1C). Instead, H&E staining of cytospins of the airway
(BAL) cells showed a greater influx of eosinophils in Treg-de-
pleted DTR/DT/RSV mice but not in WT/RSV control mice (Fig.
1D). Both eosinophils and neutrophils were detected in Treg-de-
pleted mice until day 14 postinfection (Fig. 1D and E), indicative
of an immune-mediated inflammation. Furthermore, this influx
was associatedwith an increase in eotaxin levels in the BALfluid of
Treg-depleted mice compared to findings for WT controls (Fig.
1F). Additionally, the Th2-associated cytokine interleukin 5
(IL-5) was detectable only in the airways of Treg-depleted mice
and not in those of WT mice following RSV infection (Fig. 1G).
Together, these findings suggest that Treg cells are not essential for
viral clearance but instead control the intensity and type of inflam-
matory response in the face of viral infection.
T cell responses are enhanced in the absence of Tregs. Loss of
Treg cells resulted in enhanced weight loss, peaking at day 7 (Fig.
1A), which coincides with an exuberant adaptive immune re-
sponse. Therefore, we further characterized the T lymphocyte re-
sponse in the lung and airways using flow cytometry. While there
was a notable influx of both CD4 and CD8 T cells in the lungs
and airways ofWTmice infectedwithRSV compared to results for
uninfected (DTR/DT) controls, both T cell subsets were signifi-
cantly increased on day 8 postinfection in the lungs and airways of
Treg-depleted (DTR/DT/RSV) mice, and T cell numbers re-
mained heightened to day 14 postinfection (Fig. 2A and B). We
further examined T cell activation by measuring expression of
granzyme B (GzmB), a marker of cytolytic activity, and CD11a
(integrin alpha L), a component of LFA-1 and amarker associated
with antiviral T cell responses (34). The mean fluorescence inten-
sity (MFI) of GzmB but not CD11a was increased on both CD4
and CD8 T cells in the lungs of WT mice infected with RSV
compared to results for uninfected (DTR/DT) controls (Fig. 2C
and D). However, expression of both activationmarkers was even
further enhanced on CD4 and CD8T cells in the lungs of Treg-
depleted mice infected with RSV, and this was significant at day 8
(for GzmB) or day 14 (for CD11a) postinfection. Therefore, these
data support that overactive and persistent effector T cell re-
sponses contribute to immune pathology in Treg-depleted mice
during RSV infection.
Antigen-specific CD8 T cells are increased in the respira-
tory tract and spleen of Treg-depletedmice following RSV chal-
lenge.Upon primary RSV challenge, there is a rapid expansion of
antigen-specific CD8 T cells that contribute to effective viral
clearance but may also lead to tissue pathology. The predominant
CD8 T cell epitope induced by RSV challenge in C57BL/6 mice
recognizes the RSV M protein (34). Therefore, we quantified the
M-peptide-specific CD8 T cell response in order to determine if
increased antigen-specific T cell responses could offer an explana-
tion for the enhanced pathology with loss of Treg cells.
Lungs, BAL fluid, and spleens were isolated, and cell homoge-
nateswere stimulatedwithRSVM187–195 peptide for 6 h, following
which IFN- expression was measured by intracellular flow cy-
tometry. As expected, on day 8 post-infection of WTmice, a clear
proportion of CD8 T cells expressed IFN- in response to stim-
ulationwithMpeptide, and themajority of these were localized to
the airways (BAL fluid; 16 to 26%) and lungs (11 to 20%) (Fig. 3A
and B). There were a similar proportion of M-peptide-specific
CD8 T cells in the BAL fluid of control mice and Treg-depleted
DTR mice despite the enhanced pathology in the Treg-depleted
mice. However, the total numbers of M-peptide-specific CD8 T
cells in Treg-depleted mice were increased in all of the tissues
examined compared to results for WT mice (Fig. 3C), including
results for the spleen, which suggests a less localized antiviral T cell
response in the absence of Treg cells.
We found that Treg-depletedRSV-infectedmice also develop a
notable splenomegaly compared to WT mice, an effect persisting
until day 14 postinfection (Fig. 3D). The splenomegaly was char-
acterized by expansion of bothCD4 andCD8T cells, providing
evidence of a systemic inflammatory T cell response (Fig. 3E) after
infection and Treg depletion (Fig. 3D and E). The weight loss in
infected Treg-depleted mice therefore seems to be accounted for
by enhanced local recruitment of inflammatory cells to the lung,
an excessive RSV-specific CD8 T cell response, and evidence of
systemic T cell activation.
Enhanced Th2-type airway responses in Treg-depletedmice.
In addition to antiviral CD8T cell responses, other factorsmight
contribute to excessive pulmonary pathology in the Treg-depleted
mice, and thus we decided to further characterize the CD4 T cell
responses developing in the lung and airways following RSV chal-
lenge. To address this, we examined expression of Th1- and Th2-
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FIG1 Regulatory T cells attenuate andmodify responses to RSV infection.Wild-type (WT/RSV) or Treg-depleted Foxp3DTR (DTR/DT/RSV)micewere infected
with A2 strain RSV intranasally on day 0. Uninfected wild-type (WT) or Treg-depleted (DTR/DT) mice were used as controls. (A) Illness was monitored by
recording individual body weights daily, and themean ( SEM) weight for each group, measured as a percentage of the day 0 (initial) weight, is shown. Data are
pooled from three experiments. (B) Total cells in the lung and bronchoalveolar lavage (BAL) fluid were quantified as ameasure of inflammation. (C) Expression
of the RSV L gene was quantified in the lung on days 4 and 8 postinfection by quantitative PCR. The dotted line shows the detection limit for the copy numbers
of L-gene according to the standard curve. (D) Numbers of eosinophils and neutrophils in the BAL fluid were determined by performing H&E staining on
cytospin slides and quantifying numbers by differential cell counts. (E) Representative BAL cytospins from day 14 are shown with red arrows indicating
eosinophils in Treg-depleted mice. BAL fluid supernatants were analyzed for eotaxin (F) or IL-5 (G) protein levels using a multiplex kit. Data are representative
of two or three independent experiments (n	 4 to 5 mice per group) unless otherwise indicated. WT/RSV versus DTR/DT/RSV: , P 0.0001; , P
0.001; , P 0.01; , P 0.05.
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specifying cytokines and transcription factors using intracellular
flow cytometry analysis of lung and BAL cells. Interestingly, at an
early time point (day 4 postinfection), there was a significant in-
crease in the proportion of CD4T cells expressing either IL-13 or
IFN- in the lungs of Treg-depleted mice compared to results for
WT controls, indicative of a mixed Th1- and Th2-type response
(Fig. 4A and B). Additionally, expression of the Th2-associated
transcription factor Gata3 was increased in lung cells on days 4
and 6 and in BAL cells on day 14 (Fig. 4C and D), while the
Th1-specifying transcription factor T-bet was enhanced on day 4
in the lungs only (Fig. 4E) in Treg-depletedmice compared toWT
controls. By day 14, themajority (70%) of CD4T cells in the BAL
fluid expressed Gata3, while only a small proportion (3%) ex-
pressed T-bet in Treg-depletedmice (Fig. 4C to F). These findings
correlate with the marked eosinophilia in the airways of Treg-
depleted mice (Fig. 1D), also indicative of a Th2-type immune
response.
Previous studies have shown that Foxp3 Treg cells may also
acquire expression of T helper cell-specifying transcription fac-
tors, and this appears to be important for their suppressive func-
tion in different inflammatory settings (35–38). Therefore, we ex-
amined expression of T-bet andGata3 on Foxp3Treg cells in the
airways of WT and Treg-depleted mice following RSV infection.
InWTmice, therewas a clear proportion (10%) ofCD4T cells in
the BAL fluid that coexpressed the Treg cell marker Foxp3 and the
Th1 cell marker T-bet at the peak of the adaptive response (days 6
and 8 postinfection) (see Fig. S2A in the supplemental material).
In the Treg-depleted mice, there were very few Tregs at this time
point (see Fig. S2A). However, at day 14 postinfection, Foxp3
Treg cells reappeared in the airways of the Treg-depleted group
and a high proportion (25%) of these cells coexpressed the Th2
marker Gata3 (see Fig. S2B). InWTmice, the majority of Foxp3
Treg cells left the airways by day 14, since pathology had resolved,
and instead appeared at baseline proportions in the lungs (see Fig.
S2C). These findings render further support that Treg cells func-
tion to limit effector T cell responses in the airways of RSV-chal-
lengedmice andmay switch their phenotype according to the type
of inflammatory milieu.
Overall, this study provides further evidence for the essential
role Treg cells play in controlling inflammatory T cell responses
and pathology in RSV infection. In particular, we have highlighted
novel roles for Treg cells in promoting resolution of disease by day
14 postinfection and preventing the persistence of Th2-type in-
flammation and eosinophilia.
DISCUSSION
Pulmonary disease caused by RSV infection involves a complex
interplay of inflammatory and anti-inflammatory immune re-
sponses, tightly regulated by Foxp3 Treg cells. We have now
provided evidence that Treg cells not only dampen overexuberant
and pathological T cell responses but also limit Th2-type immune
responses (e.g., Gata3- and IL-13-expressing CD4 T cells and
eosinophilic influx into the airways). Additionally, Treg cells sup-
press antiviral CD8 T cell responses and prevent systemic man-
ifestations in RSV infection. Our findings therefore support the
concept that Tregs play a central role in preventing pathology in
viral bronchiolitis.
Perhaps the most exciting finding from our studies was that
acute Treg cell depletion in the Foxp3DTR mice led to the appear-
ance of a phased and mixed Th1/Th2-type immune response fol-
lowing primary RSV infection. Previous studies have shown that
the acute loss of Treg cells alone can lead to a Th2-type immune
response and pathology without any additional antigenic stimu-
lation (39), and in allergic inflammation, acute Treg depletion at
the time of sensitization (but not challenge) leads to an enhanced
Th2-type immune response and worsening of pathology (40–43).
Mixed Th1/Th2-type immune responses (including eosinophils,
neutrophils, and both IL-13- and IFN--producing CD4T cells)
FIG 2 Treg depletion leads to enhanced activation and recruitment of T cells into the lungs and airways during RSV infection. Following infection of wild-type
(WT/RSV) and Treg-depleted (DTR/DT/RSV) mice with RSV, whole lung and bronchoalveolar lavage (BAL) fluid were harvested on days 4, 8, and 14
postinfection. CD4 (A) or CD8 (B) T cells were quantified in the BAL fluid and lung by flow cytometry analysis. Expression (mean fluorescence intensity
[MFI]) of activation markers, including GzmB and CD11a, on both CD4 (C) and CD8 (D) T cells in the lung are shown. Data are representative of two
independent experiments (n	 4 to 5 mice per group). WT/RSV versus DTR/DT/RSV: , P 0.05; , P 0.01.
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are also a feature of vaccine-enhanced RSV disease in mice and of
human bronchiolitis (44–46), indicating that dysregulation is the
hallmark of RSV disease.
We showed previously that RSV-infected Treg-depleted
DEREG mice (as well as mice infected with RSV as neonates and
rechallenged with RSV as adults) have marked eosinophilia asso-
ciated with increased disease severity (31, 47). Importantly, in the
Treg-depleted Foxp3DTR mice, both the eosinophils and Th2 cells
persist beyond the peak of the antiviral immune response and viral
clearance, suggesting that they directly contribute to the persistent
pathology as reflected by delayed recovery fromweight loss. Thus,
Treg cells not only drive an appropriate antiviral response during
RSV infection but also promote resolution of the disease.
Even more interesting was the observation that Foxp3 Treg
cells in the airways acquired expression of Gata3, a marker of Th2
cells, in Foxp3DTRmice at later time points (day 14) following RSV
infection. Previous studies have reported expression of Gata3 by
Foxp3 Treg cells in mucosal sites like the intestine and skin and
have shown that expression of Gata3 is important for Treg cell-
mediated suppression of inflammation at these sites (38). In the
FI-RSV vaccine model, trafficking of Treg cells to the airways is
dependent on CCL17 and CCL22, chemokines typically associ-
ated with Th2 cell responses and the influx of Treg cells is impor-
tant in resolution of Th2-type inflammation (32). Similarly, in the
ovalbumin (OVA) model of allergic inflammation, expression of
CCR4 (the receptor for CCL17 and CCL22) is important in the
ability of Tregs to suppress Th2 pathology (43). However, mice in
which tolerance tomaternal OVAwas induced during their wean-
ing period and which were then infected with RSV displayed an
excessive Th2-type pathology, and this included expression of
bothGata3 and Th2-type cytokines by Foxp3Treg cells, suggest-
ing that these cells acquire effector functions and contribute to
worsened disease (48). Therefore, it would be interesting in future
studies to evaluate the role of these Gata3-expressing Treg cells in
RSV disease and to determine whether they maintain their sup-
pressive function or are converting to effector T cells that contrib-
ute to pathology.
Recent work has shown that induced Treg cells (iTregs) (those
generated in the tissues) rather than thymically derived natural
Treg cells (nTregs) are important for controlling Th2 responses
and that specific depletion of iTreg cells by mutating a conserved
noncoding region in the Foxp3 gene (Foxp3
CNS1) resulted in pa-
thology (49). Although we did not distinguish between natural
and induced Treg cells in our model, it would be interesting in
further studies to determine whether RSV infection in the
Foxp3
CNS1 mouse model results in a similar enhanced pathology
or whether natural Tregs are capable of controlling the immune
response.
In RSV infection, there are conflicting data concerning the role
of Treg cells in regulating the influx of antigen-specific CD8 T
FIG 3 Peptide-specific CD8 T cell responses are enhanced in the respiratory tract and spleens of Treg-depleted mice during RSV infection. Tissues were
harvested fromwild-type (WT/RSV) or Treg-depleted (DTR/DT/RSV)mice infected with RSV at various days postinfection. Following a 6-h restimulation with
the RSV M peptide, IFN- CD8 T cells were quantified in the BAL fluid, lung, and spleen by FACS. (A and B) The frequencies of CD8 T cells expressing
M-peptide-specific IFN- among total CD8 T cells on day 8 postinfection are shown (A), with representative FACs plots (B) for the various tissues examined.
(C) Total numbers of M-peptide-specific IFN- CD8 T cells in all the tissues from Treg-depleted orWTmice on day 8 postinfection. Spleens were harvested
from RSV-infectedWT or Treg-depleted mice on days 8 and 14 postinfection. (D and E) Total spleen cells were quantified (D), and total numbers of CD8 and
CD4T cells were enumerated (E).Mice depleted of Treg cells (DTR/DT) but not infectedwith RSVwere used as controls. Data are representative of two or three
independent experiments. , P 0.05; , P 0.01; ns, not significant.
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cells in the lungs, and previous studies demonstrate that depletion
of Treg cells can either in result an inhibited or enhanced antigen-
specific T cell response (24–26, 31). We observed an enhanced
number of peptide-specific CD8 T cells in the absence of Treg
cells in all the tissues, including the spleen, after RSV infection.
This would suggest that Treg cells are important for controlling
virus-specific T cell responses not just in the airways but also sys-
temically. Furthermore, the excessive inflammatory milieu that
develops in the Treg-depleted mice could directly contribute to
aberrant activation and homing of T effector cells to a variety of
tissue sites outside the respiratory tract, thus prolonging disease
resolution. In fact, previous work has indicated that CD8 T cells
may be critical for controlling excessive Th2 responses and eosin-
ophilia in vaccine-enhanced RSV disease models (50, 51). There-
fore, the loss of CD8 T cells from the airways by day 14 postin-
fection, while the eosinophils and CD4 Th2 cells persisted, may
further indicate a lack of control of these pathological immune
cells and contribute to the persistent disease in the respiratory
tract.
Despite the enhanced antiviral T cell response, we did not see
any difference in viral loads in the lungs ofWT and Treg-depleted
mice, and these findings contrast with those of previous studies in
our group using the DEREG model of acute Treg cell depletion
(31). Similar to the Foxp3DTR model, DT treatment of DEREG
mice is effective at short-term systemic depletion of Foxp3 Treg
cells; however, DEREGmicewill not develop systemic autoimmu-
FIG 4 Regulatory T cells limit pathogenic Th2-type responses in the airways following RSV infection.Wild-type (WT/RSV) and Treg-depleted (DTR/DT/RSV)
mice were challenged with RSV, and tissues were harvested to examine CD4 T cell responses. (A and B) The frequency of CD4 T cells expressing cytokines
IL-13 and IFN- were quantified in the lung on day 4 postinfection by flow cytometry (A), and representative FACS plots are shown (B). (C and D) The
frequencies of CD4 T cells expressing the transcription factor Gata3 in the BAL fluid and the lung at various days postinfection are shown (C), with
representative FACS plots from the BAL fluid (D). (E and F) The frequencies of CD4 T cells expressing the transcription factor T-bet in the BAL fluid and lung
at various days postinfection (E) with representative FACS plots from the BAL fluid (F) are shown. Data are representative of two independent experiments (n	
3 to 4 mice per group). , P 0.05; , P 0.001.
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nity due to the gradual outgrowth of a suppressive Foxp3 GFP
population (28). In contrast, Foxp3DTR adultmicewill succumb to
a fatal autoimmunity as early as 10 days after the first DT treat-
ment if treatments are given every other day (33). While experi-
ments in this study involved only a short DT treatment course to
avoid complications from the systemic disease, it is certainly pos-
sible that the enhanced inflammation that develops in the
Foxp3DTR mice could explain differences in antigen-specific re-
sponses, pathological outcome, and viral clearance compared to
findings of previous studies using the DEREGmice or anti-CD25
treatment.
In conclusion, these studies provide further support for the
concept that Tregs perform a vital function in controlling the im-
mune response during primary RSV infections. With inadequate
Treg responses, lung pathology is enhanced and prolonged, with
an immune phenotype similar to that seen in asthma. Although
these effectsmay be transient and present only in certain phases of
disease, the long-term consequences of Th2 “imprinting” of the
respiratory mucosa (52) may account for the association between
severe infantile RSV infection and the development of wheezing
disorders in later childhood (9). If this is the case, strategies that
boost Treg responses might not only ameliorate disease but also
result in long-term improvements in respiratory health.
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